Specific allergen immunotherapy for the treatment of atopic eczema

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Tam, Herman ^a   Calderon, Moises A ^b   Manikam, Logan ^a   Nankervis, Helen ^c   García Núñez, Ignacio ^d   Williams, Hywel C ^c   Durham, Stephen ^b   Boyle, Robert J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CALCINEURIN INHIBITOR; CORTICOSTEROID; EMOLLIENT AGENT; FOOD ALLERGEN; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; PLACEBO;

ANAPHYLAXIS; ASSESSMENT OF HUMANS; ASTHMA; ATOPIC DERMATITIS; BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; DATA ANALYSIS; DATA COLLECTION METHOD; DATA EXTRACTION; DATA SYNTHESIS; DERMATOLOGY LIFE QUALITY INDEX; DERMATOPHAGOIDES; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMBASE; FOLLOW UP; FOOD ALLERGY; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INSOMNIA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PHYSICIAN; POLLEN ALLERGY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCORING ATOPIC DERMATITIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SPECIFIC ALLERGEN IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TREATMENT OUTCOME; ADULT; ANIMAL; CHILD; DERMATITIS, ATOPIC; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION; PROCEDURES;

ADULT; ALLERGENS; ANIMALS; CHILD; DERMATITIS, ATOPIC; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84969522682     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008774.pub2     Document Type: Review

References (126)

1. Di Rienzo V, Cadario G, Grieco T, Galluccio AG, Caffarelli C, Liotta, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, open, parallel-group study. Annals of Allergy, Asthma & Immunology 2014;113(6):671-3. [PUBMED: 25304342]
2. EudraCT 2008-000196-23. Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild-to-moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO-AD-1 Italy). www.clinicaltrialsregister.eu/ctr-search/trial/2008-000196-23/IT (accessed 1 December 2015).
3. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia 1994;22(1):18-22. [MEDLINE: 8030579]
4. Glover MT, Atheron DJ. A double-blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology 1991;125(Suppl s38):87.
5. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical & Experimental Allergy 1992;22(4):440-6. [MEDLINE: 1611544]
6. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo-controlled study. Annals of Allergy 1974;32(6):321-30. [MEDLINE: 4597822]
7. Leroy B, Lachapelle JM, Jacquemin MG, Saint-Remy JM. Immunotherapy of atopic dermatitis by injections of antigen-antibody complexes. Dermatology 1993;186(4):276-7. [MEDLINE: 8513198]
8. Leroy BP, Boden G, Jacquemin MG, Lachapelle JM, Saint-Remy JM. Allergen-antibody complexes in the treatment of atopic dermatitis: preliminary results of a double-blind placebo-controlled study. Acta Dermato-Venereologica. Supplementum 1992;176:129-31. [MEDLINE: 1476025]
9. Leroy BP, Boden G, Lachapelle JM, Jacquemin MG, Saint-Remy JM. A novel therapy for atopic dermatitis with allergen-antibody complexes: A double-blind, placebo-controlled study. Journal of the American Academy of Dermatology 1993;28(2 Pt 1):232-9. [MEDLINE: 8432921]
10. Luna-Pech JA, Newton-Sanchez OA, Torres-Mendoza BM, Garcia-Cobas CY. Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma & Immunology 2013;111(5 Suppl 1):A8. [EMBASE: 71306835]
11. Novak N, Bieber T, Hoffman M, Folster-Holst M, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy & Clinical Immunology 2012;130(4):925-31. [MEDLINE: 22947344]
12. Novak N, Zuberbier T, Sager A. Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE-mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology 2011;66(Suppl s94):103. [EMBASE: 70640604]
13. Pajno G, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. Journal of Allergy & Clinical Immunology 2007;120(1):164-70. [MEDLINE: 17543376]
14. Pajno G, Vita D, Caminiti L, Arrigo T, Lombardo F, Barberio G. House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy & Clinical Immunology 2006;117(2 Suppl 1):S233.
15. Pajno GB, Caminiti L, Vita D, Profazio C. Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February - 2 March 2010. Journal of Allergy & Clinical Immunology 2010;125(2 Suppl 1):AB236. [EMBASE: 70156028]
16. Passalacqua G, Compalati E, Canonica GW. Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organization Journal 2010;3(7):216-9. [MEDLINE: 23282652]
17. Passalacqua G, Pajno G. Long-term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy & Clinical Immunology 2012;67(Suppl 96):89. [EMBASE: 71109979]
18. NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015).
19. Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology 2014;53(5):650-655. [MEDLINE: 23968339]
20. Sanchez Caraballo JM, Cardona Villa R. Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online 2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240]
21. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis - Results of a double-blind, placebo-controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis - Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie 2006;29(5):171-83. [EMBASE: 2006255579]
22. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis - results of double blind placebo controlled trial. Journal of the European Academy of Dermatology & Venereology 2003;17(Suppl 3):155.
23. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study. Polski Merkuriusz Lekarski 2006;21(126):558-65. [MEDLINE: 17405298]
24. Silny W, Czarnecka-Operacz M, Silny P. Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie 2005;58(5-6):287-94. [MEDLINE: 16238119]
25. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie 2005;58(1-2):47-55. [MEDLINE: 15991553]
26. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2(8096):912-5. [MEDLINE: 81927]
27. Ariano R, Incorvaia C, La Grutta S, Marcucci F, Pajno G, Sensi L, et al. Safety of sublingual immunotherapy started during the pollen season. Current Medical Research & Opinion 2009;25(1):103-7. [MEDLINE: 19210143]
28. Brunetti L, Francavilla R, Tesse R, Fiermonte P, Dambra P, Massagli M, et al. Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome: a pilot study. Biodrugs 2005;19(6):393-9. [MEDLINE: 16392891]
29. Businco L. Early treatment of the atopic child: first results of the clinical trial. Pediatric Pulmonology - Supplement 1997;16:73. [MEDLINE: 9443210]
30. Bussmann C, Novak N. Allergen-Specific Immunotherapy in Patients With Atopic Dermatitis?. Allergologie 2007;30(11):405-10.
31. Cadario G, Galluccio AG, Pezza M, Appino A, Milani M, Pecora S, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: A prospective pilot study. Current Medical Research & Opinion 2007;23(10):2503-6. [MEDLINE: 17784996]
32. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology 2009;64(Suppl 91):1-59. [EMBASE: 2010086368]
33. Compalati E, Massimo L, Anthi R, Elisa V, Giovanni P, Giorgio WC. Abstracts of the XXIX EAACI Congress of the European Academy of Allergy and Clinical Immunology. London, United Kingdom. June 5-9, 2010. Allergy 2010;65(Suppl 92):1-756. [EMBASE: 20553234]
34. D'Souza MF, Pepys J, Wells ID, Tai E, Palmer F, Overell BG, et al. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clinical Allergy 1973;3(2):177-93. [MEDLINE: 4131252]
35. Darsow U, Forer I, Ring J. Specific Immunotherapy in Atopic Eczema [Spezifische hyposensibilisierung bei atopischem ekzem]. Allergologie 2005;28(2):53-61. [EMBASE: 2005116033]
36. Derkach V, Slavyanskaya T. Combination Immunotropic Therapy of Atopic Dermatitis in Children: Cost-Benefit Analysis. 2015 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting Houston, TX United States. Journal of Allergy & Clinical Immunology 2015;135(2 Suppl):AB265.
37. Finegold I. Immunotherapy at the ACAAI Annual Meeting. 6th International Congress on Autoimmunity, 9-13 September 2008, Porto, Portugal. Immunotherapy 2009;1(2):177-9. [MEDLINE: 20635938]
38. Gendelman S, Lang DM. Specific immunotherapy in treating atopic dermatitis: A systematic review using the GRADE system. 2011 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting San Francisco, CA United States. 18-22 March 2011. Journal of Allergy & Clinical Immunology 2011;127(2 Suppl 1):AB49. [EMBASE: 70358915]
39. Gendelman SR, Lang DM. Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Annals of Allergy, Asthma & Immunology 2013;111(6):555-61. [MEDLINE: 24267368]
40. Gendelman SR, Lang DM. Sublingual Immunotherapy in the Treatment of Atopic Dermatitis: a Systematic Review Using the GRADE System. Current Allergy & Asthma Reports 2014;15(2):1-8.
41. Gendelman S, Lang DM. Sublingual Immunotherapy in the Treatment of AtopicDermatitis: a Systematic Review Using the GRADE System. Current Allergy and Asthma Reports 2015;15(2):498.
42. Horak F. Sublingual immunotherapy: Noticeable improvement after a few weeks [SLIT - Spurbare besserung bereits nach wenigen wochen]. Atemwegs- und Lungenkrankheiten 2009;35(7):325. [EMBASE: 2009425237]
43. Incorvaia C, Mauro M, Cappelletti T, Pravettoni C, Leo G, Riario-Sforza GG. New applications for sublingual immunotherapy in allergy. Recent Patents on Inflammation & Allergy Drug Discovery 2009;3(2):113-7. [MEDLINE: 19519587]
44. Jacquemin MG, Saint-Remy JM. Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. Therapeutic Immunology 1995;2(1):41-52. [MEDLINE: 7553070]
45. Juji F, Kobayashi S, Ito S, Sugawara N, Kano H, Yasueda H, et al. Immunotherapy by Japanese cedar pollen in atopic dermatitis. Arerugi 2003;52(11):1081-8.
46. Larenas-Linnemann D. Briefings from ACAAI 2008 annual meeting. The Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology, Seattle, WA, USA, 6-11 November, 2008. Therapy 2009;6(2):279-83. [EMBASE: 2009459563]
47. Larenas-Linnemann D. Certainties and doubts about sublingual and oral immunotherapy in children. Current Opinion in Allergy & Clinical Immunology 2009;9(6):558-67. [MEDLINE: 19812482]
48. Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy, Asthma & Immunology Research 2015;7(3):221-9.
49. Leung TN, Hon KL. Eczema therapeutics in children: what do the clinical trials say?. Hong Kong Medical Journal 2015;21(3):251-260. [PUBMED: 25904389]
50. Marogna M, Braidi C, Colombo C, Colombo F, Palumbo L, Compalati E. Can sublingual allergen immunotherapy for house dust mites influence the longterm evolution of severe atopic dermatitis and the progression to respiratory allergy? Results of an observational comparison with pharmacotherapy. 34th Congress of the European Academy of Allergy and Clinical Immunology Barcelona Spain. Allergy 2015;70(Suppl):461. [EMBASE: 72029742]
51. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G, et al. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergologia et Immunopathologia 2000;28(2):54-62. [MEDLINE: 10804094]
52. Melamed IR, Robinson L, Heffron M. The Benefit of Montelukast in Atopic Dermatitis Induced by Food Allergies. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February to 2 March 2010. Journal of Allergy & Clinical Immunology 2010;125(2 Suppl 1):AB93. [EMBASE: 70155473]
53. Mihara S, Hide M. Ebm and future direction of allergen-specific immunotherapy for atopic dermatitis. Arerugi - Japanese Journal of Allergology 2008;57(5):499-506. [MEDLINE: 18520169]
54. Minelli M, Schiavino D, Musca F, Bruno ME, Falagiani P, Mistrello G, et al. Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome. International Journal of Immunopathology & Pharmacology 2010;23(1):193-201. [MEDLINE: 20378005]
55. Mohapatra SS, Qazi M, Hellermann G. Immunotherapy for allergies and asthma: present and future. Current Opinion in Pharmacology 2010;10(3):276-88. [MEDLINE: 20573547]
56. Nahm DH, Lee ES, Park HJ, Kim HA, Choi GS, Jeon SY. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. International Archives of Allergy & Immunology 2008;146(3):235-40. [MEDLINE: 18268392]
57. Niebuhr M, Kapp A, Werfel T. Specific immunotherapy in the treatment of atopic dermatitis [Spezifische Immuntherapie Bei Der Behandlung Der Atopischen Dermatitis: Hautarzt]. Hautarzt 2007;58(3):232-6. [MEDLINE: 17103200]
58. Niebuhr M, Kapp A, Werfel T. Specific immunotherapy (SIT) in atopic dermatitis and food allergy [Spezifische Immuntherapie (SIT) Bei Atopischer Dermatitis Und Nahrungsmittelallergie]. Hautarzt 2008;59(7):544-50. [MEDLINE: 18528671]
59. Noh GW, Lee KY. Interferon-gamma induced desensitization igid for house dust mites: modulation of immune status from th2 to th1 using interferon-gamma as a new therapeutic concept for atopic dermatitis. Annals of Allergy, Asthma & Immunology 2000;84:155.
60. Novak N. Allergen specific immunotherapy for atopic dermatitis. Current Opinion in Allergy & Clinical Immunology 2007;7(6):542-6. [MEDLINE: 17989532]
61. Ong PY, Boguniewicz M. Investigational and unproven therapies in atopic dermatitis. Immunology & Allergy Clinics of North America 2010;30(3):425-39. [MEDLINE: 20670823]
62. Ozdemir C. An immunological overview of allergen specific immunotherapy - Subcutaneous and sublingual routes. Therapeutic Advances in Respiratory Disease 2009;3(5):253-62. [MEDLINE: 19880430]
63. Panzani RC, Schiavino D, Nucera E, Pellegrino S, Fais G, Schinco G, et al. Oral hyposensitization to nickel allergy: preliminary clinical results. International Archives of Allergy & Immunology 1995;107(1-3):251-4. [MEDLINE: 7613144]
64. Passalacqua G, Garelli V, Sclifo F, Canonica GW, Pajno G. Immunotherapy - 2082. Long term prevention of asthma and rhinitis in children with atopic dermatitis four year after discontinuation of sublingual immunotherapy. 2nd WAO International Scientific Conference, WISC 2012 Hyderabad India. 6-9 February 2012. World Allergy Organization Journal 2013;6(Suppl 1):P163. [EMBASE: 71252379]
65. Pereira AM. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Revista Portuguesa De Imunoalergologia 2013;21(3):215-6. [EMBASE: 2014073384]
66. Petrova SI, Berzhets VM, Al'banova VI, Bystritskaia TF, Petrova NS. Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitization to house dust mites [Immunoterapia v kompleksnom lechenii bol'nykh atopicheskim dermatitom s sensibilizatsiei k kleshcham domashnei pyli]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2001;Jan-Feb(1):33-6. [EMBASE: 11236499]
67. Pons-Guiraud A. Value of Allerglobulin in the treatment of atopic dermatitis in children and young adults. A double-blind randomized study [Interet de l'allerglobuline dans le traitement de la dermatite atopique de l'enfant et de l'adulte jeune. Etude randomisee en double aveugle]. Revue De Medecine Interne 1986;7(5):537-42. [MEDLINE: 2433723]
68. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. British Journal of Dermatology 1982;107(5):597-602. [MEDLINE: 6751375]
69. Roos TC, Geuer S, Roos S, Brost H. Recent Advances in Treatment Strategies for Atopic Dermatitis. Drugs 2004;64(23):2639-66. [MEDLINE: 15537368]
70. Schiavino D, Nucera E, Alonzi C, Buonomo A, Pollastrini E, Roncallo C, et al. A clinical trial of oral hyposensitization in systemic allergy to nickel. International Journal of Immunopathology & Pharmacology 2006;19(3):593-600. [MEDLINE: 17026844]
71. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clinical & Experimental Allergy 2009;39(4):562-70. [MEDLINE: 19226280]
72. Shi H, Wang X, Ren H, Zhuang Y. Effect analysis of the dust mite allergen specific, immunotherapy of chronic eczema. Chinese Journal of Dermatovenereology 2010;24:424-6.
73. Slavyanskaya T, Derkach V. Rationale for the use of multiagent immunotherapy in children with atopic dermatitis. 33rd Congress of the European Academy of Allergy and Clinical Immunology Copenhagen Denmark. Allergy 2014;69(Suppl s99):190. [EMBASE: 71612794]
74. Slavyanskaya T, Derkach V. Clinical substantiation of immunocorrective therapy in children with atopic dermatitis. 2013 WAO Symposium on Immunotherapy and Biologics. Chicago, IL, USA 13-14 December 2013. World Allergy Organization Journal 2014;7(Suppl 1):P21. [EMBASE: 71440390]
75. Smolkin I, Pampura A, Ceburkin A, Morozova O. Influence of early specific immunotherapy by house dust mite allergens on development of asthma in children with atopic dermatitis. European Respiratory Journal 2000;16(Suppl 31):310s.
76. Stiller MJ, Shupak JL, Soter NA. The synthetic immunoregulatory pentapeptide thymopentein: an adjunctive treatment in severe atopic dermatitis. Journal of Investigative Dermatology 1993;100(4):520.
77. Stiller MJ, Shupack JL, Kenny C, Jondreau L, Cohen DE, Soter NA. A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. Journal of the American Academy of Dermatology 1994;30(4):597-602. [MEDLINE: 8157786]
78. Strannegård O, Strannegård IL, Kang K, Cooper KD, Hanifin JM. FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5). International Archives of Allergy & Applied Immunology 1982;69(3):238-44. [MEDLINE: 6752042]
79. Tammaro A, De Marco G, Persechino S, Narcisi A, Camplone G. Allergy to nickel: first results on patients administered with an oral hyposensitization therapy. International Journal of Immunopathology & Pharmacology 2009;22(3):837-40. [MEDLINE: 19822100]
80. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59(5):491-7. [MEDLINE: 15080829]
81. van Rijk RG. When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies.. Current Opinion in Allergy & Immunology 2008;8(6):565-70. [MEDLINE: 18978473]
82. Wen T, Wang E, Shen S, Jiang C, Tian R, Kang K, et al. Allergenic potency of SMU-Df extract in comparison with VUS-Df extract; and diagnosis and immunotherapy for atopic dermatitis and rhinitis with SMU-Df extract in China. Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt für Sera und Impfstoffe) zu Frankfurt Am. 1992;85:217-27. [MEDLINE: 1540294]
83. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61(2):202-5. [MEDLINE: 16409197]
84. Werfel T, Kapp A. Specific immunotherapy in atopic eczema. Allergy & Clinical Immunology International 2007;19(3):100-3. [EMBASE: 2007512301]
85. Werfel T. The role of specific immunotherapy (SIT) in atopic dermatitis. Drugs of Today 2008;44(Suppl B):47-9. [MEDLINE: 19221619]
86. Zachariae H, Cramers M, Herlin T, Jensen J, Kragballe K, Ternowitz T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Dermato-Venereologica. Supplementum 1985;65(114):48-54. [MEDLINE: 3859167]
87. Zheng J. Clinical Study on Sublingual Immunotherapy for Allergens of Children with Atopic Dermatitis. Herbal Medicine 2011;17:149-50.
88. Zolkipli Z, Roberts G, Cornelius V, Clayton CB, Pearson S, Michaelis LJ, et al. Randomised controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. 33rd Congress of the European Academy of Allergy and Clinical Immunology Copenhagen Denmark 7-11 June 2014. Allergy 2014;69(Suppl s99):105. [EMBASE: 71612566]
89. Zolkipli Z, Roberts G, Kurukulaaratchy R, Michaelis LJ, Matthews S, Clayton CB, et al. O24-Mite allergy prevention study. Clinical & Translational Allergy. 3rd Pediatric Allergy and Asthma Meeting, PAAM 2013 Athens Greece. 17-19 October 2013 2014;4(Suppl 1):O24. [EMBASE: 71812057]
90. Zolkipli Z, Roberts G, Cornelius V, Clayton B, Pearson S, Michaelis L, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. Journal of Allergy & Clinical Immunology 2015 Jun 12 [Epub ahead of print]. [DOI: 10.1016/j.jaci.2015.04.045; PUBMED: 26073754]
91. NCT00310492 . Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy of a 12-month subcutaneous specific immunotherapy with ALK-depot SQ milbenmischung in patients with atopic dermatitis and proven IgE-mediated sensitization to house dust mites. clinicaltrials.gov/show/NCT00310492 (accessed 18 Nov 2014).
92. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001186.pub2]
93. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61(8):969-987. [MEDLINE: 16867052]
94. Allam JP, Novak N. The pathophysiology of atopic eczema. Clinical & Experimental Dermatology 2006;31(1):89-93. [MEDLINE: 16309494]
95. Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014;383(9925):1297-304. [PUBMED: 24485709]
96. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Journal of Allergy & Clinical Immunology 2013;132(1):110-7. [MEDLINE: 23647790]
97. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [MEDLINE: 7786990]
98. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD008838.pub2]
99. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: A pilot study. Clinical & Experimental Allergy 2007;37(9):1277-85. [MEDLINE: 17845407]
100. Bussmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis. Journal der Deutschen Dermatologischen Gesellschaft 2009;7(3):205-19. [MEDLINE: 18759739]
101. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001936.pub2]
102. Calderon MA, Boyle RJ, Nankervis H, García Núñez I, Williams HC, Durham S. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD008774]
103. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD007685.pub2]
104. Capristo C, Romei I, Boner AL. Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: Avoidance of indoor allergens. Allergy 2004;59(Suppl 78):53-60. [MEDLINE: 15245359]
105. Committee of the Safety of Medicine. CSM update: Desensitising vaccines. British Medical Journal Clinical Research Ed. 1986;293(6552):948. [MEDLINE: 20742706]
106. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. Journal of Allergy & Clinical Immunology 2006;118(2):434-40. [PUBMED: 16890769 ]
107. Darsow U. Allergen-specific immunotherapy for atopic eczema: updated. Current Opinion in Allergy & Clinical Immunology 2012;12(6):665-9. [PUBMED: 22918221]
108. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. Journal of Allergy & Clinical Immunology 2007;120(6):1338-45. [PUBMED: 17935764 ]
109. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. New England Journal of Medicine 1999;341(7):468-75. [MEDLINE: 10441602]
110. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 9310563]
111. Gustafsson D, Sjöberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis - A prospective follow-up to 7 years of age. Allergy 2000;55(3):240-5. [MEDLINE: 10753014]
112. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [MEDLINE: 12111919]
113. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org., Available from www.cochrane-handbook.org.
114. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. Journal of Allergy & Clinical Immunology 2004;113(5):925-31. [MEDLINE: 15131576]
115. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy & Clinical Immunology 2004;113(5):832-6. [MEDLINE: 15131563]
116. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): Initial validation and practical use. British Journal of Dermatology 1995;132(6):942-9. [MEDLINE: 7662573]
117. Maintz L, Novak N. Getting more and more complex: The pathophysiology of atopic eczema. European Journal of Dermatology 2007;17(4):267-83. [MEDLINE: 17540632]
118. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variation in prevalence of eczema symptoms in children from ISAAC phase three. Journal of Allergy & Clinical Immunology 2009;124(6):1251-8. [MEDLINE: 20004783]
119. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133(3):599-609. [PUBMED: 17951626 ]
120. Purvis DJ, Thompson JM, Clark PM, Robinson E, Black PN, Wild CJ, et al. Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age. British Journal of Dermatology 2005;152(4):742-9. [MEDLINE: 15840107]
121. Rotiroti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. Journal of Allergy & Clinical Immunology 2012;130(4):918-24. [PUBMED: 22971521]
122. Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. Journal of Allergy & Clinical Immunology 1999;104(6):1280-40. [MEDLINE: 10589013]
123. Tam H, Calderon MA, Boyle RJ. Efficacy of allergen-specific immunotherapy for patients with atopic dermatitis. Journal of Allergy & Clinical Immunology 2013;132(4):1012-3. [MEDLINE: 23993878]
124. Warner JO, ETAC Study Group, Early Treatment of the Atopic Child. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' post-treatment follow-up. Journal of Allergy & Clinical Immunology 2001;108(6):929-37. [MEDLINE: 11742270]
125. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. Journal of Allergy & Clinical Immunology 2006;118(1):209-13. [PUBMED: 16815157]
126. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy 2005;60(1):4-12. [MEDLINE: 15575924]